BCR and chronic myelogenous leukemia, BCR-ABL1 positive: In addition, the BCR::ABL1 target LASP1 was identified as an interactor of CXCR4 [23], in which low LASP1 activity/expression may contribute to the CXCR4-driven survival advantage of CML cells [26].